Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine - Starton Therapeutics

Next Previous
Search
Drug Profile

Olanzapine - Starton Therapeutics

Alternative Names: CHEMIO OLANZ; CMIO-OLANZ; CMIO-OLNZ; STAR-OLZ - Starton Therapeutics

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemioCare
  • Developer Starton Therapeutics
  • Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Piperazines; Small molecules; Thiophenes
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Nausea and vomiting
  • No development reported Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting(In volunteers) in USA (Transdermal, Patch)
  • 20 May 2024 Starton Therapeutics has patent protection for Olanzapine in the US
  • 21 Feb 2023 Phase I development is ongoing in the US

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top